非酒精性脂肪性肝病和结直肠肿瘤的关系

刘思甫; 谢正元

doi:10.3969/j.issn.1001-5256.2019.09.046

非酒精性脂肪性肝病和结直肠肿瘤的关系

DOI: 10.3969/j.issn.1001-5256.2019.09.046

南昌大学第二附属医院消化内科

基金项目:

国家自然科学基金(81860119)；江西省科技厅重点研发项目(20071BBG70085)；江西省自然科学基金资助项目(20181BAB205011)；江西省教育厅技术研究项目(160162)；

详细信息

中图分类号: R575.5;R735.34
计量
- 文章访问数: 866
- HTML全文浏览量: 46
- PDF下载量: 210
- 被引次数: 0
出版历程
- 收稿日期: 2019-04-25
- 出版日期: 2019-09-20

Association between nonalcoholic fatty liver disease and colorectal tumors

Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University

Research funding:

摘要

摘要: 近年研究认为非酒精性脂肪性肝病为代谢综合征的肝脏表现,与促结直肠瘤变的因素——肥胖、胰岛素抵抗、高血压、高血脂等有关。提出了非酒精性脂肪性肝病与结直肠肿瘤的发生发展密切相关,归纳总结了非酒精性脂肪性肝病和结直肠肿瘤的关系及可能的互相影响机制,指出二者在临床、发病机制等方面存在不同程度的交叉,希望对这一领域未来的研究提供一定的参考。
- 非酒精性脂肪性肝病 /
- 结直肠肿瘤 /
- 代谢综合征X
Abstract: Recent studies have shown that nonalcoholic fatty liver disease ( NAFLD) is the manifestation of metabolic syndrome in the liver and is associated with the factors which promote colorectal neoplasia, such as obesity, insulin resistance, hypertension, and hyperlipidemia.This article points out that NAFLD is closely associated with the development and progression of colorectal tumors and summarizes the association between NAFLD and colorectal tumors and possible mechanisms. It is pointed out that NAFLD and colorectal tumors share certain clinical features and pathogenesis, which provides a theoretical basis for future research in this field.
- non-alcoholic fatty liver disease /
- colorectal neoplasms /
- metabolic syndrome X

HTML全文

参考文献(33)

[1] National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association;Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol, 2018, 34 (5) :947-957. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南 (2018年更新版) [J].临床肝胆病杂志, 2018, 34 (5) :947-957.

[2] MANTOVANI A, DAURIZ M, BYRNE CD, et al. Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy:A systematic review and meta-analysis[J]. Metabolism, 2018, 87:1-12.

[3] CHEN DZ, JI FY, XU QM, et al. Interaction of smoking and metabolic syndrome in increasing the recurrence risk of colorectal cancer in a Chinese male cohort:A retrospective study[J]. Sci Rep, 2018, 8 (1) :972.

[4] CHEN J, BIAN D, ZANG S, et al. The association between nonalcoholic fatty liver disease and risk of colorectal adenoma and cancer incident and recurrence:A meta-analysis of observational studies[J]. Expert Rev Gastroenterol Hepatol, 2019, 13 (4) :385-395.

[5] CHEN KL, MADAK-ERDOGAN Z. Estrogens and female liver health[J]. Steroids, 2018, 133:38-43.

[6] PALMISANO BT, ZHU L, STAFFORD JM. Role of estrogens in the regulation of liver lipid metabolism[J]. Adv Exp Med Biol, 2017, 1043:227-256.

[7] NIE X, XIE R, TUO B. Effects of estrogen on the gastrointestinal tract[J]. Dig Dis Sci, 2018, 63 (3) :583-596.

[8] LUGARI S, MANTOVANI A, NASCIMBENI F, et al. Hypothyroidism and nonalcoholic fatty liver disease-a chance association?[J]. Horm Mol Biol Clin Investig, 2018.[Epub ahead of print]

[9] MANTOVANI A, GRANI G. Thyroid dysfunction and nonalcoholic fatty liver disease:We need new larger and well-designed longitudinal studies[J]. Dig Dis Sci, 2018, 63 (7) :1970-1976.

[10] EFSTATHIADOU ZA, KITA MD, POLYZOS SA. Thyroid dysfunction and non-alcoholic fatty liver disease[J]. Minerva Endocrinol, 2018, 43 (3) :367-376.

[11] CHAN YX, AIFONSO H, CHUBB SA, et al. Higher thyrotropin concentration is associated with increased incidence of colorectal cancer in older men[J]. Clin Endocrinol (Oxf) , 2017, 86 (2) :278-285.

[12] ZHANG YJ, LIU YT, YU XS. Predictive value of serum liver enzyme for the metabolic syndrome[J]. Chin J Med Offic, 2017, 45 (1) :82-85. (in Chinese) 张艳君, 刘奕婷, 于晓松.血清肝酶指标对代谢综合征预测价值[J].临床军医杂志, 2017, 45 (1) :82-85.

[13] AL-DAYYAT HM, RAYYAN YM, TAYYEM RF. Non-alcoholic fatty liver disease and associated dietary and lifestyle risk factors[J]. Diabetes Metab Syndr, 2018, 12 (4) :569-575.

[14] KATSIKI N, PEREZ-MARTINEZ P, ANAGNOSTIS P, et al. Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome?[J]. Curr Vasc Pharmacol, 2018, 16 (3) :219-227.

[15] ULAGANATHAN V, KANDIAH M, MOHD SHARIFF Z. A casecontrol study of the association between metabolic syndrome and colorectal cancer:A comparison of International Diabetes Federation, National Cholesterol Education Program Adults Treatment Panel III, and World Health Organization definitions[J]. J Gastrointest Oncol, 2018, 9 (4) :650-663.

[16] PAN S, HONG W, WU W, et al. The relationship of nonalcoholic fatty liver disease and metabolic syndrome for colonoscopy colorectal neoplasm[J]. Medicine (Baltimore) , 2017, 96 (2) :e5809.

[17] FUJII H, IMAJO K, YONEDA M, et al. HOMA-IR:An independent predictor of advanced liver fibrosis in nondiabetic non-alcoholic fatty liver disease[J]. J Gastroenterol Hepatol, 2019.[Epub ahead of print]

[18] MU W, CHENG XF, LIU Y, et al. Potential nexus of non-alcoholic fatty liver disease and type 2 diabetes mellitus:Insulin resistance between hepatic and peripheral tissues[J]. Front Pharmacol, 2019, 9:1566.

[19] WALKIEWICZ K, NOWAKOWSKA-ZAJDEL E, KOZIEL P, et al. The role of some ADAM-proteins and activation of the insulin growth factor-related pathway in colorectal cancer[J].Cent Eur J Immunol, 2018, 43 (1) :109-113.

[20] OBI K, RAMSEY M, HINTON A, et al. Insights into insulin resistance, lifestyle, and anthropometric measures of patients with prior colorectal cancer compared to controls:A National Health and Nutrition Examination Survey (NHANES) Study[J]. Curr Probl Cancer, 2018, 42 (2) :276-285.

[21] WADA S, YASUNAGA Y, OKA K, et al. Submucosal fat accumulation in human colorectal tissue and its association with abdominal obesity and insulin resistance[J]. United European Gastroenterol J, 2018, 6 (7) :1065-1073.

[22] IBRAHIMI M, MOOSSAVI M, MOJARAD EN, et al. Positive correlation between interleukin-1 receptor antagonist gene86bp VNTR polymorphism and colorectal cancer susceptibility:A case-control study[J]. Immunol Res, 2019, 67 (1) :151-156.

[23] RAZI S, BARADARAN NOVEIRY B, KESHAVARZ-FATHI M, et al. IL-17 and colorectal cancer:From carcinogenesis to treatment[J]. Cytokine, 2019, 116:7-12.

[24] YANG XL, SUN XM, ZHAO XH, et al. Expressions of IL-17E, IL-17F and their receptors in colorectal carcinoma tissue and their significances[J]. J Jilin Univ:Med Edit, 2018, 44 (3) :574-578. (in Chinese) 杨学良, 孙雪梅, 赵晓晖, 等. IL-17E和IL-17F及其受体在结直肠癌组织中的表达及其意义[J].吉林大学学报:医学版, 2018, 44 (3) :574-578. (in Chinese)

[25] GHAZI-KHANLOOSANI M, BANDEGI AR, KOKHAEI P, et al. CRP and LOX-1:A mechanism for increasing the tumorigenic potential of colorectal cancer carcinoma cell line[J].Pathol Oncol Res, 2018.[Epub ahead of print]

[26] MANDAL P. Molecular mechanistic pathway of colorectal carcinogenesis associated with intestinal microbiota[J]. Anaerobe, 2018, 49:63-70.

[27] MA C, ZHANG Q, GRETEN TF. Nonalcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes[J]. FEBSJ, 2018, 285 (4) :752-762.

[28] HOFFMANOVA I, SANCHEZ D, TUCKOVA L, et al. Celiac disease and liver disorders:From putative pathogenesis to clinical implications[J]. Nutrients, 2018, 10 (7) :e892.

[29] de FARIA GHETTI F, OLIVEIRA DG, de OLIVEIRA JM, et al.Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis[J]. Eur J Nutr, 2018, 57 (3) :861-876.

[30] MANTOVANI A, DAURIZ M, BYRNE CD, et al. Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy:A systematic review and meta-analysis[J].Metabolism, 2018, 87:1-12.

[31] WU K, ZHAI MZ, WELTZIEN EK, et al. Non-alcoholic fatty liver disease and colorectal cancer survival[J]. Cancer Causes Control, 2019, 30 (2) :165-168.

[32] PENG J, CHEN Y, DONG XL, et al. Association between KRAS gene mutations and clinicopathological characteristics and prognosis of colorectal cancer patients[J]. Chin J Dig Surg, 2018, 17 (2) :143-147. (in Chinese) 彭健, 陈颖, 董先龙, 等. KRAS基因突变与结直肠癌患者临床病理特征及预后的关系[J].中华消化外科杂志, 2018, 17 (2) :143-147.

[33] DOLATKHAH R, SOMI MH, SHABANLOEI R, et al. Main risk factors association with proto-oncogene mutations in colorectal cancer[J]. Asian Pac J Cancer Prev, 2018, 19 (8) :2183-2190.

施引文献

资源附件(0)

访问统计